TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today opinion published Oct. 20 argues that a more pro-vaccine Congress after the 2026 midterms may not prevent further changes to vaccine policy. The authors point to executive-branch authority, possible renewed actions by HHS Secretary Robert F. Kennedy Jr., and state-level proposals, while noting that election outcomes and future policy decisions remain uncertain.
A MedPage Today opinion published Oct. 20 argues that the 2026 midterms are unlikely, by themselves, to shield vaccine policy from further changes, even if more pro-vaccine lawmakers enter Congress. Authors Steven Grossman, JD, and Michael Miller, MD, say executive-branch actions and state legislation could continue to affect vaccine recommendations and access after the new Congress convenes on Jan. 3, 2027.
Grossman and Miller forecast that vaccine advocates will have more allies in Congress next year, while cautioning that this would not necessarily constrain the administration’s actions. Their discussion of election results is a projection, not a final count: the opinion says a Democratic takeover of the House appeared near certain in mid-October polling, while control of the Senate was described as a 50-50 possibility.
The authors say that in 2026, advocates coordinated responses to federal and state actions affecting vaccines. They cite a lawsuit challenging changes to the Advisory Committee on Immunization Practices (ACIP) and reductions in routine vaccine recommendations. They also describe medical societies issuing their own routine vaccination guidance that, they say, largely mirrored pre-2025 ACIP recommendations. These are the authors’ accounts of developments and their significance.
The opinion also points to responses to changes involving HHS and FDA advisory groups, respiratory-vaccine recommendations, and state efforts to expand school vaccine exemptions. Grossman and Miller argue that the public-health response was uneven: they cite competing national concerns, a mild 2025-26 flu season, and the administration’s response to measles outbreaks as factors that kept vaccine policy from becoming a larger election issue. The piece does not provide an independent assessment of those factors.
Congressional Gains May Have Limits
The authors’ central argument is that election results may not translate directly into control over federal vaccine policy. Congress can legislate and oversee executive agencies, but the opinion warns that disputes over executive authority and compliance with court rulings could complicate those checks. That concern matters to patients, clinicians and public-health agencies because federal recommendations can shape routine vaccination guidance, while state rules affect requirements and exemptions.
The piece also stresses that vaccine policy is not decided at one level of government. Even if Congress becomes more supportive of vaccination, state-level proposals and federal agency decisions may continue to change the rules people encounter. The article is an argument about risks ahead, not confirmation that specific new policies will be adopted.
Products Worth Considering
Therabody Theragun Prime 6th Generation Deep Tissue Massage Gun, Navy
Garmin Forerunner 165 GPS Running Smartwatch, 43 mm, Black
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
The 2026 Policy and Advocacy Picture
Grossman and Miller frame their analysis against vaccine-policy disputes dating to 2025, when, they write, policies pursued by President Donald Trump and HHS Secretary Robert F. Kennedy Jr. expanded. In response, they say, advocacy groups formed informal coalitions and coordinated opposition to actions affecting vaccine recommendations and advisory bodies.
The authors also describe a shift in the administration’s approach during 2026. They say Kennedy temporarily pursued less direct policies after controversies over ACIP, while maintaining his broader views and policy agenda. They cite increased NIH research into vaccine injuries as an example of a topic they viewed as less likely to dominate midterm campaigning. Their account presents this as interpretation; the article does not establish what future actions Kennedy will take.
““Heavy lifting from pro-vaccine policymakers and advocates will be essential over the next 2 years, but this need will likely stretch into 2029 and beyond.””
— Steven Grossman, JD, and Michael Miller, MD, in their MedPage Today opinion
Election Results and Policy Remain Open
At publication, the 2026 election outcome was not yet settled, and the authors’ expectations about House and Senate control were based on mid-October polling. It is not yet clear which party will control either chamber, what legislation lawmakers will pursue, or whether Congress will take action on vaccine policy.
The opinion predicts that Kennedy may pursue new policies or revive proposals previously blocked after the midterms. Those are the authors’ forecasts, not confirmed decisions. The source material does not specify which proposals would return, when they might be issued, how courts would rule, or how federal agencies and states would respond. It also does not establish that the administration will disregard any particular future court order.
The New Congress Takes Office
The new Congress is scheduled to convene on Jan. 3, 2027. Election results will determine the balance of power and the committee and oversight roles available to lawmakers, but the source does not identify any scheduled vaccine-policy vote or specific next administrative action.
Developments to watch include federal agency decisions and advisory-panel changes, congressional oversight, court proceedings over vaccine policy, and state proposals affecting school exemptions. Whether any of these produces a substantial shift will depend on actions that had not been confirmed when the opinion was published.
Key Questions
What is the main argument of the opinion?
Grossman and Miller argue that a more pro-vaccine Congress after the 2026 midterms may not prevent federal executive actions or state-level proposals affecting vaccine policy.
Were the 2026 midterm results known when the article was published?
No. The Oct. 20 opinion describes expected outcomes based on mid-October polling. Control of Congress had not been established in the source material.
What vaccine-policy dispute do the authors cite?
They cite a lawsuit challenging changes to ACIP and reductions in routine vaccine recommendations, along with medical societies issuing guidance they say largely matched pre-2025 ACIP recommendations.
Has Kennedy announced a new post-election vaccine policy?
The source material does not report a specific new policy announcement. The authors predict he may pursue new or previously blocked measures, but that remains a forecast.
Source: rss
![A Walkable ASCII Cyberpunk City In One HTML File [Video]](https://yogafitdaily.com/wp-content/uploads/2026/09/a-walkable-ascii-cyberpunk-city-in-one-html-file-video-featured-560x300.jpg)
